$SRNE News Article - Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido and Expects to Complete Enrollment on its SP-102 (SEMDEXA(TM)) Phase 3 Pivotal Trial Program in 2020
https://marketwirenews.com/news-releases/scil...27124.html